Question to the Cabinet Office:

To ask the Minister for the Cabinet Office, if he will make an assessment of the potential merits of recognising mono-HCV haemophiliacs as a separate cohort under the Infected Blood Compensation Scheme.

In March, Parliament approved the Infected Blood Compensation Scheme Regulations 2025, which established the Infected Blood Compensation Scheme in full and gave the Infected Blood Compensation Authority the powers it needs to begin making payments to all people eligible for compensation under the Scheme.

In line with the recommendations from the Infected Blood Inquiry’s second interim report and Sir Robert’s compensation framework study, the Infected Blood Compensation Scheme takes a tariff based approach to compensation based on infection severity bands. The Government sought advice on the infection severity bandings and consequent tariffs from the Infected Blood Inquiry Response Expert Group.

In regards to an additional award for haemophiliacs, the scope of the scheme’s supplementary route is in line with the recommendations Sir Robert Francis KC made to the Government in August 2024. The Government accepted Sir Robert’s recommendation that, with the exception of autonomy awards to victims of unethical research, supplementary route awards should only be available for care and financial loss.